Lilly’s weekly insulin works as well as daily products, new studies show; Obesity drug from Roche succeeds in early test, sending company shares up

Taking stock of the drug industry, from the lab to the medicine chest

May 16, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Lilly's weekly insulin works as well as daily products, new studies show A weekly insulin could be more convenient for patients to take over daily options, especially since it matches the weekly regimen of GLP-1 diabetes drugs. By Elaine Chen STAT+ | Obesity drug from Roche succeeds in early test, sending company shares up Roche shares were up early Thursday morning, signaling the keen interest in the increasingly competitive obesity field. By Andrew Joseph STAT+ | Biogen, Ionis drop ALS treatment after study failure The companies said Thursday they would discontinue the program, another setback in drug development for the neurodegenerative condition. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser